1.2511
price down icon1.95%   -0.0289
 
loading
前日終値:
$1.28
開ける:
$1.28
24時間の取引高:
24,746
Relative Volume:
0.05
時価総額:
$3.19M
収益:
-
当期純損益:
$-8.26M
株価収益率:
-0.0233
EPS:
-53.609
ネットキャッシュフロー:
$-12.17M
1週間 パフォーマンス:
-4.92%
1か月 パフォーマンス:
-4.20%
6か月 パフォーマンス:
-90.50%
1年 パフォーマンス:
-96.23%
1日の値動き範囲:
Value
$1.23
$1.284
1週間の範囲:
Value
$1.20
$1.40
52週間の値動き範囲:
Value
$1.10
$43.69

Gri Bio Inc Stock (GRI) Company Profile

Name
名前
Gri Bio Inc
Name
セクター
Healthcare (1171)
Name
電話
(619) 400-1171
Name
住所
2223 AVENIDA DE LA PLAYA, LA JOLLA
Name
職員
4
Name
Twitter
Name
次回の収益日
2024-11-12
Name
最新のSEC提出書
Name
GRI's Discussions on Twitter

GRI を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
GRI
Gri Bio Inc
1.2533 3.19M 0 -8.26M -12.17M -53.61
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.12 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.62 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
316.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
239.94 28.51B 3.81B -644.79M -669.77M -6.24

Gri Bio Inc Stock (GRI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-09 開始されました H.C. Wainwright Buy

Gri Bio Inc (GRI) 最新ニュース

pulisher
Jun 14, 2025

Q2 Earnings Estimate for GRI Bio Issued By HC Wainwright - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Kalkine : GRI Bio Advancing in the Nasdaq Composite Healthcare Space - Kalkine Media

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio (NASDAQ:GRI) Receives “Buy” Rating from HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

HC Wainwright Reiterates Buy Rating for GRI Bio (NASDAQ:GRI) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio’s (GRI) Buy Rating Reiterated at HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio (NASDAQ:GRI) Given “Buy” Rating at HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio (NASDAQ:GRI) Earns Buy Rating from HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio’s (GRI) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

# H.C. Wainwright REITERATES Buy rating on GRI Bio stock By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

# H.C. Wainwright REITERATES Buy rating on GRI Bio stock - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

GRI Stock Maintains Buy Rating and $10 Price Target | GRI Stock News - GuruFocus

Jun 11, 2025
pulisher
May 28, 2025

GRI Bio (NASDAQ:GRI) Price Target Cut to $34.00 by Analysts at Ascendiant Capital Markets - Defense World

May 28, 2025
pulisher
May 27, 2025

GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Sto - GuruFocus

May 27, 2025
pulisher
May 27, 2025

GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Stock News - GuruFocus

May 27, 2025
pulisher
May 24, 2025

GRI Bio (NASDAQ:GRI) Trading Down 4% – Here’s Why - Defense World

May 24, 2025
pulisher
May 23, 2025

GRI Bio expands at-the-market offering capacity By Investing.com - Investing.com Nigeria

May 23, 2025
pulisher
May 23, 2025

GRI Bio Expands Share Offering Agreement - TipRanks

May 23, 2025
pulisher
May 23, 2025

GRI Bio expands at-the-market offering capacity - Investing.com

May 23, 2025
pulisher
May 22, 2025

GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary Fibrosis Treatment | GRI Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

GRI Bio Reports Positive Preclinical Data For GRI-0621 - Nasdaq

May 22, 2025
pulisher
May 22, 2025

GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary F - GuruFocus

May 22, 2025
pulisher
May 22, 2025

GRI Bio IncPhase 2A Study Results For GRI-0621 Expected In Q2 2025 - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

GRI Bio reports progress in pulmonary fibrosis treatment By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

GRI Bio reports progress in pulmonary fibrosis treatment - Investing.com

May 22, 2025
pulisher
May 22, 2025

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results - The Manila Times

May 22, 2025
pulisher
May 22, 2025

GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

GRI Bio Advances in IPF Treatment with Promising Trial Results - TipRanks

May 22, 2025
pulisher
May 21, 2025

GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

GRI Bio CEO Reveals Next Steps in NKT Cell Therapy Development at Virtual Investor Series - Stock Titan

May 21, 2025
pulisher
May 16, 2025

GRI Bio meets interim clinical trial enrollment goal for IPF therapy - Pulmonary Fibrosis News

May 16, 2025
pulisher
May 16, 2025

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - The Manila Times

May 16, 2025
pulisher
May 16, 2025

GRI Bio CEO Reveals Latest Developments in Revolutionary NKT Cell Technology at Major Healthcare Conference - Stock Titan

May 16, 2025
pulisher
May 15, 2025

GRI Bio reports positive early trial data for IPF treatment By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

GRI: Q1 Financial Report Highlights and Future Prospects | GRI S - GuruFocus

May 15, 2025
pulisher
May 15, 2025

GRI Bio reports positive early trial data for IPF treatment - Investing.com

May 15, 2025
pulisher
May 15, 2025

GRI: Q1 Financial Report Highlights and Future Prospects | GRI Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 - The Manila Times

May 15, 2025
pulisher
May 15, 2025

GRI Bio, Inc. Reports Positive Phase 2a Interim Safety and Biomarker Results for GRI-0621 in Idiopathic Pulmonary Fibrosis Treatment - Nasdaq

May 15, 2025
pulisher
May 15, 2025

GRI Bio, Inc. SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 15, 2025

GRI Bio Reports First Quarter 2025 Financial Results and - GlobeNewswire

May 15, 2025
pulisher
May 09, 2025

GRI Bio reports positive interim biomarker data in IPF study By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 08, 2025

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect Of GRI-0621 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

GRI Bio reports positive interim biomarker data in IPF study - Investing.com

May 08, 2025
pulisher
May 08, 2025

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

GRI Bio Continues To Drive Enrollment In Ongoing Phase 2A Study Of GRI-0621 In Idiopathic Pulmonary Fibrosis - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ('IPF”) - The Manila Times

May 07, 2025
pulisher
May 02, 2025

GRI Bio (GRI) to Release Earnings on Friday - Defense World

May 02, 2025
pulisher
Apr 24, 2025

GRI Bio Inc (GRI) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com

Apr 24, 2025
pulisher
Apr 17, 2025

FY2025 Earnings Forecast for GRI Bio Issued By HC Wainwright - Defense World

Apr 17, 2025

Gri Bio Inc (GRI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
大文字化:     |  ボリューム (24 時間):